Jagruti Rehabilitation Center | ₹28 Cr (Series A)

Pune-based Jagruti Rehabilitation Centre has raised ₹28 crore in a Series A round led by Alkemi Growth Capital, its first institutional funding, to expand its network of mental health, addiction and dementia care centres.

The round

Jagruti raised ₹28 crore (Rs 28 crore) in Series A funding led by Alkemi Growth Capital, a Delhi-based venture fund focused on healthcare and consumer wellness, BioSpectrum India reported. Until now the network grew through internal accruals. No other investors or valuation were disclosed.

The funds will go to entering new geographies, expanding clinical and staff capacity, building specialised care programmes and deepening insurance and corporate partnerships. Jagruti plans to reach more than 40 centres and 4,000 beds across Tier I and Tier II cities over the next three to four years.

"This first institutional investment is an important milestone in Jagruti's journey." — Dr Amar Shinde, Founder and Director, Jagruti Rehabilitation Centre

What Jagruti does

Jagruti was founded in 2008 by Dr Amar Shinde and provides residential care for mental health conditions, substance-use disorders and dementia. According to Medical Dialogues, it runs more than 19 centres across nine cities with more than 1,600 beds and over 40 doctors, and has supported more than 82,000 people. Cities include Pune, Mumbai, Delhi NCR, Ahmedabad, Bengaluru and Chennai. These are company figures.

More coverage is under Jagruti Rehabilitation Center funding news, with related stories for Pune startups.

The investors

Alkemi Growth Capital's listed portfolio includes Redcliffe Labs, Medvital, Datar Cancer Genetics, Medulance, Alphadroid and Leumas. Jagruti is its first investment in mental health and rehabilitation within healthcare delivery.

"Mental health is one of the largest and least institutionalised gaps in Indian healthcare." — Alka Goel, Founder and Managing Partner, Alkemi Growth Capital

Goel also pointed to delivering psychiatrist-led care to a consistent clinical standard at prices middle-income families can afford, per Medical Dialogues.

Why it matters

BioSpectrum describes care in this segment as mostly delivered by standalone clinics and small independent establishments, which leaves room for organised providers. It gives no market-size figures, and none are cited here. For investors the question is whether a bed-heavy network can keep clinical quality consistent as it adds centres. Related funding stories sit under HealthTech funding news.